Serum and Liver Lipidome Following Empagliflozin Administration for Six Months in a Fast Food Diet Mouse Model.

ABSTRACT: Empagliflozin is a sodium-glucose co-transporter inhibitor approved for the treatment of type 2 diabetes mellitus. The aim of this study was the 6-month effect of empagliflozin on serum and liver lipidome in C57BL/6J mice fed on a fast food diet (FFD). Three groups were studied; two of them fed on FFD, one with empagliflozin (EMPA group), and another without empagliflozin (FFD group); the third group fed on a chow diet and served as the control group (CD group). Following untargeted lipidomic analysis, the FFD and EMPA groups displayed largely similar serum lipid profiles, characterized by elevated levels in the majority of identified lipids, compared with the CD group, particularly glycerophospholipids. For instance, phosphatidylcholine (PC) 34:1 and phosphatidylinositol (PI) 38:3 increas

SUBMITTER: Makri ES 

PROVIDER: S-EPMC12524644 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature